The nation of Zimbabwe has declined a substantial US health deal valued at 367 million US dollars (272 million pounds) spanning five years due to Washington's insistence on sensitive biological samples.
The decision was revealed after a internal memorandum from December was leaked, indicating that Head of State Emmerson Mnangagwa felt the deal was "skewed".
An official spokesperson later stated that the United States was seeking health data for scientific study and commercial purposes while refused to guarantee the benefits from future medical innovations.
"We are forced to start the challenging and unfortunate process of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided over $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for continued dialogue to reach a deal agreeable to both sides so the country's critical HIV programme can be sustained.
Broader Background
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a court halted a related health funding agreement following legal challenges were filed about the safety of Kenyans' medical information.
After returning to office last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen aid for the US government, but Trump argued its spending was "wasteful" and his administration was seeking direct bilateral deals to boost transparency and accountability.
Based on reports, Sixteen nations in Africa have so far signed similar agreements, representing more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership would have delivered extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy via US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no corresponding assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"In essence, our nation would supply the raw materials for medical research without any certainty that the end products would be accessible to our people if a new health crisis arise."
National Interest and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining structures already established via the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to deal with future pandemics.
"This framework is designed to ensure that when a country provides its data, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to develop them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We are open to ongoing discussions with our American counterparts on how future co-operation could be designed in a way that honours the sovereignty and dignity of both nations."
Health Experts Reaction
Medical experts expressed it recognised the official position, but suggested that negotiations should continue given that much of the nation's HIV programmes relied on foreign aid.
"If specific concerns exist, including those involving information security or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," it commented.
This impasse highlights the complex challenges between accepting vital international aid and safeguarding local interests in an increasingly data-driven world.